ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Drugmakers fund research at U.K. schools

by Alex Scott
February 6, 2017 | APPEARED IN VOLUME 95, ISSUE 6

[+]Enlarge
Credit: Novo Nordisk
A rendering of Novo’s planned research center at Oxford.
Credit: Novo Nordisk
A rendering of Novo’s planned research center at Oxford.

Two drug companies have formed collaborations with leading U.K. universities. Novo Nordisk and the University of Oxford are joining to discover novel approaches for treating type 2 diabetes. As part of the agreement Novo will establish a research center at the university that will employ up to 100 scientists. The Danish firm expects to invest about $150 million in the initiative over 10 years. The partners say they seek cross-fertilization of ideas between academics and Novo researchers. Novo already funds 32 fellows at the university as a result of a 2013 pact. Separately, Heptares Therapeutics will fund efforts by Anthony Davenport’s group at the University of Cambridge to discover molecules that target the apelin receptor, a G protein-coupled receptor implicated in a range of cardiovascular diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment